Cross Shore Discovery Fund | | | | | | | | | | | | | |
Schedule of Investments (Unaudited) | | | | | | | | | | | | | |
June 30, 2023 | | | | | | | | | | | | | |
| | | | | | | | | | | | | |
Portfolio Funds* | | % of Net Assets | | Cost(1) | | Fair Value | | Initial Acquisition Date | | Redemption Frequency(2) | | Next Available Redemption Date | |
| | | | | | | | | | | | | |
Long/Short Generalist: | | | | | | | | | | | | | |
Atika Offshore Fund, Ltd., Class A, Series 1 | | 4.6% | | $ 677,447 | | $ 1,480,296 | | 1/2/2015 | | Quarterly | | 9/30/2023 | |
| | | | | | | | | | | | | |
EVR Offshore Partners Fund, Ltd., Class B, Series 1121 | | 5.5% | | 1,750,000 | | 1,774,346 | | 11/1/2021 | | Quarterly | | 9/30/2023 | (3) |
| | | | | | | | | | | | | |
Hawk Ridge Partners Offshore, Ltd., Class A, Initial Series | | 8.7% | | 1,600,000 | | 2,813,807 | | 2/1/2018 | | Quarterly | | 9/30/2023 | |
| | | | | | | | | | | | | |
Hill City Capital Offshore Fund Ltd., Class A, Series 14 | | 6.4% | | 1,750,000 | | 2,051,329 | | 11/1/2021 | | Quarterly | | 9/30/2023 | (3) |
| | | | | | | | | | | | | |
TCIM Offshore Fund Ltd., Class A-33, Series 2019-12 | | 7.9% | | 1,756,890 | | 2,536,633 | | 12/1/2019 | | Monthly | | 7/31/2023 | |
| | | | | | | | | | | | | |
Thames Absolute Return Offshore Fund, Ltd., Class B-2, Series 1 | | 5.8% | | 1,550,000 | | 1,861,055 | | 11/1/2017 | | Quarterly | | 9/30/2023 | |
| | | | | | | | | | | | | |
Wolf Hill Offshore Fund, Ltd., Class A-OS, Series 2020-08 | | 5.2% | | 1,300,000 | | 1,685,933 | | 7/1/2021 | | Quarterly | | 9/30/2023 | |
| | | | | | | | | | | | | |
Total Long/Short Generalist | | 44.1% | | 10,384,337 | | 14,203,399 | | | | | | | |
| | | | | | | | | | | | | |
Long/Short Sector: | | | | | | | | | | | | | |
Energy | | | | | | | | | | | | | |
Encompass Capital Fund Offshore Ltd., Class A, Series 1 | | 10.8% | | 1,803,039 | | 3,461,916 | | 1/1/2020 | | Quarterly | | 9/30/2023 | |
| | | | | | | | | | | | | |
Healthcare, Biotechnology | | | | | | | | | | | | | |
Avoro Life Sciences Offshore Fund Ltd., Class A-1 | | 12.0% | | 1,069,545 | | 3,875,042 | | 5/1/2017 | | Quarterly | | 9/30/2023 | |
Biomedical Offshore Value Fund, Ltd., Class I, Series 200199-1 | | 10.0% | | 2,100,000 | | 3,218,803 | | 1/1/2019 | | Quarterly | | 9/30/2023 | |
| | | | | | | | | | | | | |
Total Healthcare, Biotechnology | | 22.0% | | 3,169,545 | | 7,093,845 | | | | | | | |
| | | | | | | | | | | | | |
Healthcare, Consumer | | | | | | | | | | | | | |
Armistice Capital Offshore Fund Ltd., Class A, Series 2019-04B | | 0.0% | (5) | 17,040 | | 1,890 | | 4/1/2019 | | N/A | | (4) | |
Armistice Capital Offshore Fund Ltd., Class A, Series 2015-09B | | 0.0% | (5) | 4,503 | | 984 | | 9/1/2015 | | N/A | | (4) | |
Armistice Capital Offshore Fund Ltd., Class A, Series 2013-08B | | 0.0% | (5) | 3,108 | | 745 | | 1/2/2015 | | N/A | | (4) | |
Total Healthcare, Consumer | | 0.0% | (5) | 24,651 | | 3,619 | | | | | | | |
| | | | | | | | | | | | | |
Technology, Media and Telecommunications | | | | | | | | | | | | | |
Atreides Foundation Fund, Ltd., Founders Class, Series F-2 | | 8.3% | | 1,585,524 | | 2,657,282 | | 5/15/2019 | | Quarterly | | 9/30/2023 | (3) |
| | | | | | | | | | | | | |
Total Long/Short Sector | | 41.1% | | 6,582,759 | | 13,216,662 | | | | | | | |
| | | | | | | | | | | | | |
Total Investments In Portfolio Funds | | 85.2% | | $ 16,967,096 | | $ 27,420,061 | | | | | | | |
Money Market Funds | | % of Net Assets | | Cost | | Fair Value | | Shares | | | | |
| | | | | | | | | | | | |
Federated Hermes Institutional Prime Obligations Fund, | | | | | | | | | | | | |
Institutional Class, 5.19%(6) | | 8.7% | | $ 2,810,761 | | $ 2,810,604 | | 2,810,322 | | | | |
| | | | | | | | | | | | |
Total Investments | | 93.9% | | $ 19,777,857 | | $ 30,230,665 | | | | | | |
| | | | | | | | | | | | |
Other Assets in Excess of Liabilities | | 6.1% | | | | $ 1,966,946 | | | | | | |
| | | | | | | | | | | | |
Net Assets | | 100.0% | | | | $ 32,197,611 | | | | | | |
| | | | | | | | | | | | |
* Non-income producing security. | | | | | | | | | | | | |
(1) There were no unfunded capital commitments as of June 30, 2023. | | | | | | | | | | | | |
(2) Certain redemptions may be subject to various restrictions and limitations such as redemption penalties on investments liquidated within a certain period subsequent to investment (e.g., a soft or hard lock-up), investor-level gates and/or Portfolio Fund-level gates. Redemption notice periods range from 30 to 120 days. |
(3) Subject to 25% investor level quarterly gate. | | | | | | | | | | | | |
(4) Redemptions are not permitted until the underlying special investments are sold/liquidated. | | | | | | | | |
(5) Amount is less than 0.05%. | | | | | | | | | | | | |
(6) Rate disclosed is the seven day effective yield as of June 30, 2023. | | | | | | | | | | | | |